[Corrections] Correction to Lancet Infect Dis 2025; published online Jan 10. https://doi.org/10.1016/S1473-3099(24)00669-8

Di |2025-01-25T00:30:01+01:00Gennaio 25th, 2025|Categorie: Coronavirus Lancet|

Krolewiecki A, Stella S, Fleitas PE, et al. Albendazole–ivermectin co-formulation for the treatment of Trichuris trichiura and other soil-transmitted helminths: a randomised phase 2/3 trial. Lancet Infect Dis 2025; published online Jan 10. https://doi....

[Correspondence] Disseminated mpox in an immunocompromised patient in DR Congo: a call for a shift from disease-focused to person-centred outbreak response

Di |2025-01-23T00:30:01+01:00Gennaio 23rd, 2025|Categorie: Coronavirus Lancet|

This Correspondence examines a complex case of an immunocompromised patient at an mpox treatment centre in South Kivu, DR Congo, highlighting the shortcomings of outbreak-focused care models and their inability to address broader health-care needs.

[Articles] Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study

Di |2025-01-21T00:30:01+01:00Gennaio 21st, 2025|Categorie: Coronavirus Lancet|

RSV vaccination was effective in preventing RSV-related illness, including associated health-care use, in adults aged 60 years and older during the 2023–24 respiratory illness season, supporting current recommendations for vaccination in this populatio...

[Grand Round] Syphilitic bi-valvular endocarditis and myocarditis: modern tools applied to long-forgotten complications of a re-emerging disease

Di |2025-01-18T00:30:01+01:00Gennaio 18th, 2025|Categorie: Coronavirus Lancet|

The incidence of syphilis has increased steadily over the past 25 years. Undiagnosed cases have presumably increased in the same proportions, and rare complications are at particularly high risk of being unrecognised. A previously healthy 60-year-old m...

[Corrections] Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00665-0

Di |2025-01-18T00:30:01+01:00Gennaio 18th, 2025|Categorie: Coronavirus Lancet|

Bennett JC, Deloria Knoll M, Kagucia EW, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 2024; publ...

[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 23. https://doi.org/10.1016/S1473-3099(24)00527-9

Di |2025-01-17T00:30:01+01:00Gennaio 17th, 2025|Categorie: Coronavirus Lancet|

Macià D, Campo JJ, Jairoce C, et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a...

[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 23. https://doi.org/10.1016/S1473-3099(24)00527-9

Di |2025-01-17T00:30:01+01:00Gennaio 17th, 2025|Categorie: Coronavirus Lancet|

Macià D, Campo JJ, Jairoce C, et al. The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a...

[Articles] Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial

Di |2025-01-16T00:30:01+01:00Gennaio 16th, 2025|Categorie: Coronavirus Lancet|

SPAQ and dihydroartemisinin–piperaquine effectively reduced malaria in children younger than 5 years, with no safety concerns. There was no evidence of resistance selection by SMC. Although these findings support SPAQ-based SMC in Eastern and Southern ...

[Articles] Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial

Di |2025-01-16T00:30:01+01:00Gennaio 16th, 2025|Categorie: Coronavirus Lancet|

SPAQ and dihydroartemisinin–piperaquine effectively reduced malaria in children younger than 5 years, with no safety concerns. There was no evidence of resistance selection by SMC. Although these findings support SPAQ-based SMC in Eastern and Southern ...

Torna in cima